



Biocept to Supply COVID-19 Testing Through Partnership With the Foundation for California Community Colleges

April 28, 2021

Foundation offers COVID-19 testing and support to more than 2.1 million students as part of campus health services

SAN DIEGO--(BUSINESS WIRE)--Apr. 28, 2021-- [Biocept, Inc.](#) (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has partnered with the Foundation for California Community Colleges to make COVID-19 testing available to the 116 California community colleges and their more than 2.1 million students.

Through the Foundation's [CollegeBuys](#) program, Biocept's PCR-based COVID-19 test is now available for community colleges to purchase for students, faculty and staff. Access to and availability of testing will provide information needed to help protect the safety of campus populations and reduce the spread of the virus on campuses and in surrounding communities if/when colleges return from the current remote learning environment as a result of the COVID-19 pandemic.

"As colleges prepare for in-person instruction, COVID-19 testing is going to be critically important in keeping campuses and students healthy and safe," said Michael Nall, President and CEO of Biocept. "We are proud to leverage our molecular testing capabilities to support California's community colleges and their students, faculty and staff during these unprecedented times."

"Expanding access to COVID-19 testing supplies is essential to smart and safe reopening strategies for the California Community Colleges—safeguarding the health and wellness of our students, faculty and staff," said Jorge J.C. Sales, Vice President of Program Development at the Foundation for California Community Colleges.

Biocept will provide colleges with PCR-based COVID-19 testing, which detects the genetic information of the virus, through its CLIA-certified, CAP-accredited San Diego laboratory. The assay detects the presence of SARS-CoV-2 and is intended for use with patients who meet current guidance for evaluation of infection with COVID-19. The test is administered by a health care provider using a nasal or oral swab, and most results will be available within 48 hours of Biocept's receipt of the sample, reducing lengthy turnaround times.

This partnership and the access to COVID-19 testing for the colleges are made possible through the Foundation's CollegeBuys program, the systemwide procurement vehicle which leverages the purchasing power of the 116 colleges to offer a number of services and products at up to 85% discount, ensuring colleges can meet the educational needs of students.

About the Foundation for California Community Colleges

The Foundation for California Community Colleges is the official nonprofit foundation to the California Community Colleges Board of Governors and Chancellor's Office. The Foundation's mission is to benefit, support, and enhance the missions of the California Community Colleges system, the largest higher education system in the nation. Incorporated in 1998, the Foundation works to benefit all California Community College students, colleges, college foundations, and the system as a whole by accelerating paths to economic and social mobility, strengthening communities, and reducing barriers to opportunities for all Californians. The Foundation is a 501(c)(3) tax-exempt non-profit organization. For more information, visit www.foundationccc.org.

About CollegeBuys

CollegeBuys is the Foundation's systemwide procurement vehicle that leverages the buying power of California's 116 community colleges to offer discounts of up to 85 percent on a wide range of educational products—from industry-leading software and technology to high quality office and classroom furniture. For more information, visit www.collegebuys.org.

About Biocept

Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide™ cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector™ technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic. For more information, visit www.biocept.com. Follow Biocept on [Facebook](#), [LinkedIn](#) and [Twitter](#).

Forward-Looking Statements

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements regarding our ability to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these

statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20210428005228/en/>

Media Contact:

Andrea Sampson, Sampson PR Group
asampson@sampsonprgroup.com, 562-304-0301

Investor Contact:

Jody Cain, LHA Investor Relations
Jcain@lhai.com, 310-691-7100

Source: Biocept, Inc.